Abstract
Osteoporotic fractures cause major morbidity and mortality in the aging
population. Genome-wide association studies (GWAS) have identified
USF3 as the novel susceptibility gene of osteoporosis. However,
the functional role in bone metabolism and the target gene of the bHLH
transcription factor USF3 are unclear. Here we show that USF3
enhances osteoblast differentiation and suppresses osteoclastogenesis in
cultured human osteoblast-like U-2OS cells. Mechanistic studies revealed
that transcription factor USF3 antagonistically interacts with
anti-osteogenic TWIST1/TCF12 heterodimer in the WNT16 and
RUNX2 promoter, and counteracts CREB1 and JUN/FOS in the
RANKL promoter. Importantly, the osteoporosis GWAS lead SNP
rs2908007 risk A allele abolishes USF3 binding in the WNT16
promoter, conferring allele-specific downregulation of the
osteoclastogenesis suppressor WNT16. While the risk G allele of
osteoporosis GWAS lead SNP rs4531631 facilitates binding of CREB1 and
JUN/FOS in the RANKL promoter, resulting in enhanced
transactivation of RANKL, the principal contributor to
osteoclastogenesis. Our findings uncovered functional mechanisms of
osteoporosis novel GWAS associated gene USF3 and lead SNPs
rs2908007 and rs4531631 in the regulation of bone formation and
resorption.